Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?

NCT ID NCT05025293

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial compares giving zoledronate, a yearly intravenous bone-strengthening drug, within 5 days of hip fracture surgery versus waiting 3 months. The goal is to see if early treatment is as safe and effective at reducing bone turnover and preventing future fractures. Participants are adults over 50 who had a low-energy hip fracture and surgery within 72 hours. The study measures bone turnover markers and recovery outcomes like mobility and delirium.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Zoledronic acid (an intravenous bisphosphonate given once yearly to strengthen bones)
What this could lead to
If early zoledronate works as well as delayed treatment, hip fracture patients could start protecting their bones sooner, potentially reducing the risk of another fracture.
What could go wrong
This is a non-inferiority trial, so it may show early treatment is not as good. Risks include kidney issues, low calcium, and side effects from the infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIP FRACTURES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Oslo University Hospital

    Oslo, Oslo, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.